Disease Activity and Safety during Long-Term (104-Week) Treatment with Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from a Phase III, Randomized, Controlled Trial and Open-Label Extension
Servicios
Servicios
Fecha de publicación
2015Título de revista
Arthritis and Rheumatology
Tipo de contenido
Publicación de congreso
